Business Description
Helix BioPharma Corp
NAICS : 325412
SIC : 3741
ISIN : CA4229101098
Description
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | -0.75 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 21 | |||||
| 3-Year EPS without NRI Growth Rate | 24.6 | |||||
| 3-Year FCF Growth Rate | 30.1 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 17.48 | |||||
| 9-Day RSI | 25.71 | |||||
| 14-Day RSI | 29.09 | |||||
| 6-1 Month Momentum % | -5.03 | |||||
| 12-1 Month Momentum % | -5.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.51 | |||||
| Quick Ratio | 0.51 | |||||
| Cash Ratio | 0.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.7 | |||||
| Shareholder Yield % | -4.85 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -1063.06 | |||||
| ROA % | -350.66 | |||||
| ROIC % | -2383.97 | |||||
| ROC (Joel Greenblatt) % | -15013.37 | |||||
| ROCE % | -1057.44 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -8.24 | |||||
| EV-to-EBITDA | -8.26 | |||||
| EV-to-FCF | -7.22 | |||||
| Earnings Yield (Greenblatt) % | -12.14 | |||||
| FCF Yield % | -13.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:HBPCF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Helix BioPharma Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.023 | ||
| Beta | -0.06 | ||
| Volatility % | 3.43 | ||
| 14-Day RSI | 29.09 | ||
| 14-Day ATR ($) | 0.000051 | ||
| 20-Day SMA ($) | 0.1377 | ||
| 12-1 Month Momentum % | -5.03 | ||
| 52-Week Range ($) | 0.1377 - 0.148 | ||
| Shares Outstanding (Mil) | 229.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Helix BioPharma Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Helix BioPharma Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Helix BioPharma Corp Frequently Asked Questions
What is Helix BioPharma Corp(HBPCF)'s stock price today?
The current price of HBPCF is $0.14. The 52 week high of HBPCF is $0.15 and 52 week low is $0.14.
When is next earnings date of Helix BioPharma Corp(HBPCF)?
The next earnings date of Helix BioPharma Corp(HBPCF) is .
Does Helix BioPharma Corp(HBPCF) pay dividends? If so, how much?
Helix BioPharma Corp(HBPCF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers